<h3>Objective:</h3> To address the identified practice gap, we created an on-line CME program. We evaluated the effectiveness of this online educational intervention to improve knowledge, competence, and confidence among neurologists regarding non-oral acute pharmacotherapies for the management of migraine. <h3>Background:</h3> Non-oral acute pharmacotherapies are recommended for patients with migraine who fail oral treatments, have prominent nausea and or vomiting or who have rapid onset attacks. These treatments are underutilized by neurologists. <h3>Design/Methods:</h3> The online continuing medical education (CME) activity format consisted of a 30-minute video discussion between three expert headache specialists. Educational effect was assessed by comparing neurologist responses to four identical questions presented before and directly after the intervention. Appropriate test statistics for the pre- post-design were used. Cohen’s d was used to calculate the effect size of the online education. Data from the participants were collected between March 23, 2022 and May 4, 2022. <h3>Results:</h3> Participation in the CME intervention resulted in a moderate educational effect size among neurologists (n=94; <i>d</i>=.51; <i>p</i><0.001). The following areas showed significant (<i>P</i> <.05) pre- vs post-educational improvements: interpretation of scoring from the Migraine Disability Assessment tool, role of gastroparesis in reducing the efficacy of oral acute migraine therapies, and the selection of an appropriate non-oral acute migraine therapy. After participating in the activity, 57% of neurologists reported an increase in their confidence in personalizing the selection of non-oral acute therapies for patients with migraine. <h3>Conclusions:</h3> The results indicated that the CME-certified 30-minute video discussion between physician experts was effective at improving awareness among neurologists and PCPs regarding the use of non-oral acute migraine therapies. Future educational efforts should continue address the importance of route of administration as a factor in the personalization of treatment for patients with migraine. <b>Disclosure:</b> Christine Considine has nothing to disclose. Dr. Finnegan has nothing to disclose. Mrs. Merlo has nothing to disclose. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amgen. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biohaven. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for GlaxoSmithKline. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Teva. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vedanta. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Lipton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Lipton has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Grifols. Dr. Lipton has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Allergan/Abbvie. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biohaven. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. Dr. Lipton has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Lipton has stock in Biohaven. Dr. Lipton has stock in Manistee. The institution of Dr. Lipton has received research support from Teva. The institution of Dr. Lipton has received research support from Amgen. The institution of Dr. Lipton has received research support from Allergan/Abbvie. The institution of Dr. Lipton has received research support from Gammacore. The institution of Dr. Lipton has received research support from Axsome. The institution of Dr. Lipton has received research support from Charleston Labs. The institution of Dr. Lipton has received research support from Eli Lilly. The institution of Dr. Lipton has received research support from Satsuma. The institution of Dr. Lipton has received research support from NIH . The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NINDS. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from NIA. The institution of Dr. Lipton has received research support from NIH. The institution of Dr. Lipton has received research support from Veterans Administration. The institution of Dr. Lipton has received research support from NIH. Dr. Lipton has received publishing royalties from a publication relating to health care.